Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.

Chih-Wan LinWei-I HuangPi-Hui ChaoWen-Wen ChenFei-Yuan Hsiao

Published in: International journal of clinical practice (2019)

Febuxostat can be considered an alternative for patients carrying risk factors for allopurinol-related CARs. However, since there were fatal cases of febuxostat-related CARs, the closely monitoring of symptoms of CARs during the initiation of febuxostat is still warranted.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
patient reported outcomes
depressive symptoms